Long acting insulin is not.
They are different products, and the formers patent being free has nothing to do with the later innovations being locked down.
Long acting insulin is not.
They are different products, and the formers patent being free has nothing to do with the later innovations being locked down.
Modern insulin is protected by moats, two of which are intellectual property and regulatory approval. Modern insulin being cheaper in other countries is because they are not following the same trade and approval laws. The way to match abroad prices would be to change protections and approvals, the latter of which is and has been happening over the last five years.
Average prices per "standard unit"
* Rapid acting: $120 (US) vs $13.50 (JP)
* Rapid-int (?) acting: $107(US) vs. $13 (JP)
* Short-acting: $87 (US) vs $19 (FR)
* Short-int acting: $95 (US) vs $13 (JP)
* Intermediate acting: $73 (US) vs $13 (JP)
* Long acting: $88 (US) vs $15 (JP)
Based on https://www.rand.org/pubs/research_reports/RRA788-1.htmlhttps://www.goodrx.com/healthcare-access/research/how-much-d...
It is more expensive in the United States because the US is subsidizing the earnings requirements the companies who make the drug require to develop new variants. At a high level, everybody pays insurance, it gets funneled into high drug prices, high drug prices pay shareholders and fund R&D. It's capitalisms version of socialized drug creation, and the rest of the world benefits from the US overpaying.
CVS filled a month supply for me after my insurance number had changed and when I went to pick it up they kindly asked for $1300 before I gave them the new insurance info.
But yes, I didn't leave a complete comment.